Sanctuary Advisors LLC grew its holdings in shares of Solventum Co. (NYSE:SOLV - Free Report) by 95.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,074 shares of the company's stock after buying an additional 9,323 shares during the period. Sanctuary Advisors LLC's holdings in Solventum were worth $1,351,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MML Investors Services LLC boosted its stake in Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock worth $373,000 after acquiring an additional 168 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Solventum by 4.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock valued at $346,000 after purchasing an additional 200 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Solventum by 4.0% in the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company's stock worth $314,000 after purchasing an additional 236 shares in the last quarter. IVC Wealth Advisors LLC grew its stake in shares of Solventum by 5.0% in the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock worth $464,000 after buying an additional 318 shares during the last quarter. Finally, KKM Financial LLC increased its position in Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company's stock valued at $304,000 after buying an additional 319 shares in the last quarter.
Several equities research analysts have commented on SOLV shares. Stifel Nicolaus started coverage on Solventum in a report on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price on the stock. Wolfe Research assumed coverage on shares of Solventum in a research report on Thursday, September 26th. They set a "peer perform" rating on the stock. Piper Sandler raised their price objective on shares of Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research note on Friday, November 8th. Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. Finally, Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $68.29.
Get Our Latest Stock Analysis on SOLV
SOLV opened at $66.83 on Friday. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a 50 day moving average price of $70.90 and a 200-day moving average price of $63.50.
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.